Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00991939 · ClinicalTrials.gov registry record · Phase 3

Initial Treatment of Patients With Immune Thrombocytopenic Purpura

A Phase 3 study, sponsored by Carelon Research.

Terminated
Registry status
Phase 3
Development phase
8
Enrollment target

NCT00991939 is a Phase 3 study that was terminated before completion, run by Carelon Research. The registered enrollment target is 8 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00991939, a Phase 3 study, was terminated before completion, sponsored by Carelon Research.

TERMINATED
Registry status
Phase 3
Development phase
8 participants
Enrollment target

Study Summary

This study will compare treatment with 3 courses of high-dose dexamethasone versus treatment with prednisone, for patients recently diagnosed with immune thrombocytopenic purpura (ITP). The primary hypothesis is that patients treated with high-dose dexamethasone will obtain a more durable remission than patients treated with prednisone.

Interventions

  • DRUG Prednisone
  • DRUG Dexamethasone USP Micronized

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2010-01
Est. Completion 2013-03
Phase Phase 3

Sponsor

Carelon Research

50 total trials

What the Registry Record Tells You About NCT00991939

The ClinicalTrials.gov registry entry for NCT00991939 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Prednisone is the first listed.

NCT00991939 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00991939 about?

NCT00991939 is a clinical study titled "Initial Treatment of Patients With Immune Thrombocytopenic Purpura". This study will compare treatment with 3 courses of high-dose dexamethasone versus treatment with prednisone, for patients recently diagnosed with immune thrombocytopenic purpura (ITP). The primary hypothesis is that patients treated with high-dose dexamethasone will obtain a more durable remission ...

What is the current status of trial NCT00991939?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2010-01. Estimated completion is 2013-03.

What interventions are being tested in trial NCT00991939?

The interventions under investigation include: Prednisone (DRUG), Dexamethasone USP Micronized (DRUG).

Who is sponsoring clinical trial NCT00991939?

This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.